---
title: "Tesamorelin research summary and literature | Sable Peptides"
description: "Tesamorelin: what the published literature covers, how it compares with Ipamorelin, key facts (CAS 218949-48-5, MW 5136) and 3 verified PubMed citations."
canonical: https://www.sablepeptides.co.uk/research/tesamorelin
dateModified: 2026-10-14
publisher: Sable Peptides Limited (UK company 17488610)
note: Research use only. Not for human or veterinary use.
---

[Research summaries](/research)

# Tesamorelin: research summary

For laboratory research use only. Not for human or veterinary use. This page summarises published literature. It gives no advice on use.

## What the literature covers

Tesamorelin (TH9507) is a synthetic analogue of growth-hormone-releasing factor (GRF). It contains the 44-amino-acid GRF sequence with a trans-3-hexenoyl group added at the N-terminus, which makes it more resistant to enzymatic breakdown.

Published reviews describe its pharmacology as a GRF analogue, and population pharmacokinetic models have been published. In receptor terms it acts on the GHRH receptor, the same target as native GRF.

It is a large peptide, with a molecular weight of about 5136 g/mol (C221H366N72O67S). At this size, mass spectrometry for identity and HPLC for purity are both important on the CoA.

## Key facts

|  | Tesamorelin | Ipamorelin |
| --- | --- | --- |
| CAS | 218949-48-5 | 170851-70-4 |
| Formula | C221H366N72O67S | C38H49N9O5 |
| Molecular weight (g/mol) | 5136 | 711.9 |

Source: [PubChem CID 16137828](https://pubchem.ncbi.nlm.nih.gov/compound/16137828).

## Tesamorelin compared with Ipamorelin

Tesamorelin and Ipamorelin both relate to growth-hormone release but act on different receptors. Tesamorelin is a 44-residue GHRH-receptor agonist built on the GRF sequence. Ipamorelin is a pentapeptide that acts on the ghrelin (GHS-R1a) receptor.

[Full side-by-side: Tesamorelin vs Ipamorelin](/versus/ipamorelin/tesamorelin)

## Frequently asked questions

What receptor does Tesamorelin act on?

The growth-hormone-releasing hormone (GHRH) receptor, the same receptor as native GRF.

How is Tesamorelin different from native GRF?

It has the GRF(1-44) sequence with an N-terminal trans-3-hexenoyl modification, which improves its stability against enzymes.

Why is identity testing important for Tesamorelin?

At about 5.1 kDa, truncated or modified sequences are possible, so the CoA's mass-spectrometry result confirms the intact molecule.

## Published literature cited

1.  González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. (2015). Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. *Clin Pharmacokinet*. [PMID 25358450](https://pubmed.ncbi.nlm.nih.gov/25358450/) · [doi:10.1007/s40262-014-0202-x](https://doi.org/10.1007/s40262-014-0202-x)
2.  Wang Y, Tomlinson B. (2009). Tesamorelin, a human growth hormone releasing factor analogue. *Expert Opin Investig Drugs*. [PMID 19243281](https://pubmed.ncbi.nlm.nih.gov/19243281/) · [doi:10.1517/13543780802707658](https://doi.org/10.1517/13543780802707658)
3.  Tomlinson B. (2006). Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. *Curr Opin Investig Drugs*. [PMID 17086939](https://pubmed.ncbi.nlm.nih.gov/17086939/)

Every citation was looked up by PMID in Europe PMC (MEDLINE) on 2026-10-14 and its title matched. Citation means the paper exists and is relevant to the compound. It does not mean the paper supports any use.

## On this site

-   [Tesamorelin vials, sizes and prices](/tesamorelin-uk)
-   [Tesamorelin reference record](/ref/tesamorelin)
-   [Tesamorelin UK price check](/uk-price-check/tesamorelin)
-   [Certificates of Analysis](/coa)

Tesamorelin (TH9507) is a synthetic analogue of growth-hormone-releasing factor (GRF). It contains the 44-amino-acid GRF sequence with a trans-3-hexenoyl group added at the N-terminus, which makes it more resistant to enzymatic breakdown. This page summarises 3 verified PubMed papers and compares Tesamorelin with Ipamorelin. Research use only; no human-use guidance is given.

Updated 2026-10-14